Vaxxinova announces acquisition of Labovet and strengthens its presence in the animal health market
Transaction reinforces the strategic importance of Brazil and Latin America in the global expansion of the Vaxxinova group
Sao Paulo, Brazil, December 15, 2025 – Vaxxinova completed the acquisition of Labovet on December 15, 2025, strengthening its presence in the Brazilian animal health market and reinforcing its growth strategy in Latin America. The transaction highlights Brazil’s strategic role in Vaxxinova’s international expansion plans.
“With the acquisition of Labovet, Vaxxinova further consolidates its position as a key player in the catle and pet markets in Brazil and Latin America,” says Hugo Scanavini Neto, Managing Director of Vaxxinova Brazil.
Headquartered in the Netherlands and part of the German EW Group, Vaxxinova maintains its Brazilian headquarters in Vargem Grande Paulista, São Paulo. In Brazil, the company’s operations are dedicated to the prevention of diseases in production animals, as well as companion animals.
Present in more than 75 countries, the Vaxxinova group operates research centers, manufacturing facilities, and diagnostic units in The Netherlands, Germany, Italy, Norway, Japan, Jordan, the United States, South Africa, Croatia and Brazil, supporting its global innovation-driven strategy in animal health.
Founded in 1990 and headquartered in Feira de Santana, in the state of Bahia, Labovet has evolved over 35 years as one of Brazil’s leading producers of biological products. The company focuses on the development, production, and commercialization of vaccines, sera, and other animal health solutions for production animals and companion animals,
“We see a perfect cultural and strategic fit between Labovet and Vaxxinova. Now, as part of Vaxxinova and the EW Group, Labovet will have the necessary support for its strategic growth,” says Fernando Falcão, founder of Labovet.
With the completion of the transaction, both companies will continue to operate independently, preserving their structures, teams, and brands, while assessing synergies aligned with the group’s long-term vision for the animal health market.
